Location History:
- Toulouse, FR (2000 - 2003)
- New York, NY (US) (2008 - 2011)
- Saint Herblain, FR (2011 - 2015)
Company Filing History:
Years Active: 2000-2015
Title: Maha Ayyoub: Innovator in Cancer Research
Introduction
Maha Ayyoub is a prominent inventor based in New York, NY (US). She has made significant contributions to the field of cancer research, particularly through her innovative work on tumor-associated peptides. With a total of 8 patents, her inventions are paving the way for advancements in cancer diagnosis and treatment.
Latest Patents
Among her latest patents are the SSX-2 peptides presented by HLA class II molecules. This invention describes HLA class II binding peptides encoded by the SSX-2 tumor-associated gene. The peptides stimulate the activity and proliferation of CD4T lymphocytes, providing methods and products for diagnosing and treating conditions characterized by the expression of the SSX-2 gene. Another notable patent is related to SSX-4 peptides presented by HLA class II molecules. Similar to the SSX-2 invention, this patent describes HLA class II binding peptides encoded by the SSX-4 tumor-associated gene, also stimulating CD4T lymphocyte activity and proliferation.
Career Highlights
Maha Ayyoub is affiliated with the Ludwig Institute for Cancer Research Limited, where she continues her groundbreaking work. Her research focuses on the development of innovative therapeutic strategies for cancer treatment.
Collaborations
Maha collaborates with esteemed colleagues, including Danila Valmori and Jean Edouard Gairin. These partnerships enhance her research efforts and contribute to the advancement of cancer therapies.
Conclusion
Maha Ayyoub's contributions to cancer research through her patents and collaborations highlight her role as an influential inventor in the field. Her work continues to inspire advancements in the diagnosis and treatment of cancer.